Research Use Only. Not for use in diagnostic tests.
Before ordering
Independent certificate details, manufacturer IDs, and batch IDs should be reviewed before purchase when available.
Order cancellations for full refunds are available before shipment; shipped orders cannot be cancelled or refunded.
For damaged or incorrect goods, photograph the outer packaging, inner packaging, and product labels, then email support within 48 hours of carrier delivery.
Swipe horizontally or use the left and right arrow keys to see all product details.
Scroll tables horizontally to view all columns.
5-Amino-1MQ
5-Amino-1MQ, also written as 5-amino-1-methylquinolinium, is a small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor used in metabolic research. Available draft box combinations are 20mg, 50mg, and 100mg, built from 10mg vials.
Product Format
10mg vials
Vial Size
10mg
Vial Capacity
3 mL
Box Combinations
20mg, 50mg, 100mg
Cost per milligram
$1.95 – $2.80
Multi-vial Purity
99.66%
Endotoxin Screening
PASSED
Heavy Metals Screening
PASSED
Purity Screening
PASSED
Doubly Validated
YES
Independently Tested
YES
Peptide Partners Manufacturer ID: WF03
Batch ID: AM202604
CAS: 42464-96-0
Molecular Formula: C10H11IN2
Research Studies
(for educational purposes only)
Selective and Membrane-Permeable Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Reverse High Fat Diet-Induced Obesity in Mice
Authors: Harshini Neelakantan, Virginia Vance, Michael D. Wetzel, Hua-Yu Leo Wang, Stanton F. McHardy, Celeste C. Finnerty, Jonathan D. Hommel, Stanley J. Watowich
This preclinical study evaluated methylquinolinium-based inhibitors of nicotinamide N-methyltransferase (NNMT), including 5-amino-1-methylquinolinium. The researchers reported that 5-Amino-1MQ showed high membrane permeability and selectivity for NNMT without inhibiting structurally related SAM-dependent methyltransferases or enzymes in the NAD+ salvage pathway. In cultured adipocytes, NNMT inhibition reduced intracellular 1-methylnicotinamide, increased NAD+ and SAM, and suppressed lipogenesis. In diet-induced obese mice, systemic treatment with an NNMT inhibitor significantly reduced body weight, white adipose tissue mass, adipocyte size, and plasma total cholesterol without changing total food intake or producing observable adverse effects in the study window.
In plain English
This is the core animal/mechanism paper for 5-Amino-1MQ. The compound was studied as an NNMT inhibitor — not as an appetite suppressant. In cells and mice, blocking NNMT shifted metabolic chemistry in a way that increased NAD+ and SAM availability and reduced fat-building signals. The mouse data are promising, but they are preclinical and do not establish human outcomes.
Reduced Calorie Diet Combined With NNMT Inhibition Establishes a Distinct Microbiome in DIO Mice
Authors: Andrea Dimet-Wiley, Qinglong Wu, Jerrin T. Wiley, Aditya Eswar, Harshini Neelakantan, Tor Savidge, Stanley J. Watowich
This study examined diet-induced obese mice treated with a nicotinamide N-methyltransferase inhibitor, identified as 5-amino-1-methylquinolinium, while switching from a Western/high-fat diet to a low-fat diet. The NNMT inhibitor plus diet switch produced a distinct cecal microbiome profile compared with diet switch alone. Reported changes included increased Lactobacillus and decreased Erysipelatoclostridium, with microbiome patterns correlating with rapid normalization of body weight and adiposity measures toward lean-control levels. The study used 16S rRNA sequencing and adipose-tissue metabolite correlation analyses to evaluate treatment-associated microbial and metabolic shifts.
In plain English
This mouse study looked beyond weight change and asked whether NNMT inhibition changes the gut microbiome during diet-driven weight loss. The researchers found that adding the NNMT inhibitor produced a different microbial signature than diet change alone. It supports the idea that NNMT inhibition may interact with broader metabolic systems, but it remains animal research.
Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes
This review summarizes evidence linking NNMT activity with obesity and type 2 diabetes biology. NNMT methylates nicotinamide using S-adenosylmethionine, which can alter NAD+ salvage chemistry, methyl-donor balance, and downstream energy-metabolism pathways. The review discusses 5-Amino-1MQ as a membrane-permeable NNMT inhibitor that reduced intracellular 1-methylnicotinamide, increased NAD+, suppressed lipogenesis, and reduced body weight in preclinical models. It also notes that NNMT knockdown or inhibition has been associated with increased energy expenditure, reduced fat mass, and improved insulin-sensitivity markers in animal and cellular studies.
In plain English
This paper is a broader review of the target that 5-Amino-1MQ acts on. NNMT is involved in how cells handle nicotinamide, NAD+, methyl groups, fat storage, and glucose metabolism. The review places 5-Amino-1MQ inside that larger NNMT research landscape and makes clear that the strongest evidence is still preclinical.
